CRP and Cirrhosis: Our data therefore supports the use of IL-6, along with leukocyte count, CRP, bilirubin, and serum creatinine, as potential biomarkers to monitor disease progression and the inflammatory burden associated with EF DNA positivity in patients with decompensated cirrhosis and ACLF (36, 65–69).